Case Report

Paget’s disease of bone presenting with multiple cranial nerve palsies: A case report✩,✩✩

M. Hamid, MDa,⁎, F. Touarsa, MDb, A. Satte, MDa, A. Bourazza, MDa

a Department of Neurology, Mohammed V Military Instruction Hospital, Rabat Morocco
b Department of Radiology, Avicenna University Hospital, Rabat Morocco

ARTICLE INFO

Article history:
Received 2 January 2022
Revised 3 March 2022
Accepted 9 March 2022

Keywords:
Paget’s disease of bone
Multiple cranial nerve palsies
Sphenoid bone
Bisphosphonates

ABSTRACT

Paget’s disease of bone (PDB) is a progressive monostotic or polyostotic osteopathy with unknown cause. It is associated with the involvement of the nervous system. The cranial nerves, spinal roots, cauda equina, spinal cord, and brain can be affected in PDB due to their close anatomical relation to bone. Hearing loss occurs in 12%-50% of patients with PDB. The optic nerve can be affected at the optic canal. The diagnosis of PDB is radiological by highlighting characteristic lesions like thickening of the cortical bone, hypertrophic and fibbrially bones. Progressive or chronic neurological deficits should be treated with bisphosphonates. We present a rare case of multiple cranial nerve palsies as the first manifestation of PDB.

© 2022 Published by Elsevier Inc. on behalf of University of Washington.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

Introduction

First described by James Paget in 1886, Paget’s disease of bone (PDB) is a progressive monostotic or polyostotic osteopathy with unknown cause. It occurs in patients above 50 years old with male predominance and represents the second acquired osteopathy behind osteoporosis [1].

The involvement of the nervous system in PDB is infrequent. The uncontrolled growth of bones can affect the brain, spinal cord, and cranial nerves. Headaches, dizziness, and deafness are the most common neurological signs of the disease [2]. In this report, we present an unusual case of multiple cranial nerve palsies as the first manifestation of PDB.

Case report

A 60-year-old man was admitted to our neurological department for a progressive decrease in visual acuity in the right eye. Three months before admission, he reported hearing loss of the right ear, vertigo, and continuous right hemifacial neuralgia. His medical history included hypertension treated with enalapril.

The neurological examination revealed a conscious patient with a supple neck. Examination of muscle strength and sensitivity was normal. Muscle stretch reflexes were normal. Motor coordination was normal. On ophthalmological examination, visual acuity was 1 of 10 in the right eye and 7 of 10 in

✩ Competing Interests: The authors have declared that no competing interests exist.
✩✩ Patient consent: Patient consent is obtained for the publication.
⁎ Corresponding author.
E-mail address: hamidsim19@gmail.com (M. Hamid).
https://doi.org/10.1016/j.radcr.2022.03.028
1930-0433/© 2022 Published by Elsevier Inc. on behalf of University of Washington. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
Facial computed tomography showed an over-riding enlarged bone, widening of the diploic space, typical 'cotton wool appearance' and stenosis of both foramen rotundum more pronounced on the right side (Fig. 1). Axial reconstruction demonstrated thickened and disorganized trabeculae, narrowing of the optic nerve canals and of the inferior orbital fissure (Fig. 2).

Cerebral MRI showed on T2 weighted images cortical thickening, expansion of the sphenoidal bone and of the petrous temporal bones (Fig. 3). CISS sequence through the cerebello-pontine angles revealed bilateral asymmetric stenosis of the internal acoustic meatus with compression of the right acoustic-facial complex nerves (Fig. 4).

Blood tests revealed an alkaline phosphatase (ALP) level of 2200 U/L (reference range, 32–91 U/L). Large paraclinical tests were performed and all went negative (serum calcium, serum magnesium, lactate dehydrogenase, parathyroid hormone, 25-hydroxy-vitamin D, thyroid hormone, hemogram, serum electrolytes, renal and hepatic tests).

As a result, the patient was diagnosed with multiple cranial nerve palsies caused by PDB. He was immediately treated with risedronate 30 mg/day and carbamazepine. Three months after the treatment, the patient noticed a gradual improvement of the trigeminal neuralgia, while hearing loss and visual acu-
Fig. 3 – Cranial MRI on axial (E) and coronal (F) T2 weighted sequence showing thickened cortex, coarsened trabeculae with an expansion of the sphenoidal bone and of the petrous temporal bone.

Fig. 4 – CISS sequence through the cerebellopontine angles showing stenosis of the internal acoustic meati more pronounced on the right side with compression of the right acoustic-facial complex nerves (arrows).

ity remained stable. Blood tests showed 40% decline in ALP. We decided the initiation of alendronate sodium 70 mg once a week while risedronate sodium treatment was terminated. A new reexamination of the patient was scheduled after 3 months.

Discussion

PDB is a focalized osteopathy touching single or many bones without including the entire skeleton. The prevalence of PDB represents 2%-3% of patients over 55 years of age [3]. In 40% of cases, PDB is discovered in the asymptomatic phase before the appearance of bone deformities. PDB etiology remains unknown, but virus hypotheses and genetic factors were pronounced [1].

PDB is associated with the involvement of the nervous system. The cranial nerves, spinal roots, cauda equina, spinal cord and brain can be affected in PDB due to their close anatomical relation to bone. Neurological syndromes are myelopathy brainstem, cerebellar dysfunction, cauda equina syndrome, radiculopathies and cranial neuropathies [4].

Apart from auditory involvement, the neurological complications of PDB are rare [5]. In the study by Clarke et al [6], 34%
of 96 patients diagnosed with PDB had cranial nerve involvement. 13 patients had an auditory involvement, one patient had a trigeminal sensory loss, and no case of optic nerve involvement.

Hearing loss occurs in 12%-50% of patients with PDB. It is caused by a lesion of the cochlea or by compression of the eighth cranial nerve in the auditory canal. The optic nerve can be affected by compression of the optic canal causing reduction of vasa nervorum flow. Clinical manifestations are diminished vision, papilledema retinal, optic atrophy, and choroiditis. Trigeminal neuralgia and facial numbness can be caused by a narrowing of the foramen of the branches of the trigeminal nerve [7].

The diagnosis of PDB is radiological. Plain radiographs show characteristic lesions such as thickening of the cortical bone, hypertrophic or fibrillar bones. Body scintigraphy increases the diagnostic sensitivity of the disease. MRI scanning is important to demonstrate the compression of neural structures and to exclude other causes [5].

Urine hydroxyproline and serum ALP concentrations are increased in patients with neurological complications in PDB due to the osteoblast hyperactivity [1].

Few cases of cranial nerve palsies in PDB have been previously reported in the literature [8–10]. Our patient had typical radiological lesions of PDB with evidence of multiple cranial nerve palsies. It is recommended that progressive neurological deficits should initially be treated with bisphosphonates [5]. The therapeutic efficiency in PDB with multiple cranial nerve palsies is not well documented. Bisphosphonates can stabilize hearing loss. Calcitonin with etidronate could stabilize the optic neuropathy [11]. Trigeminal neuralgia improves with carbamazepine. Intravenous bisphosphonates is an alternative to oral bisphosphonates treatment failure [12].

Conclusion

The neurological complications of PDB are rare and can be severe. Clinicians should consider PDB as a possible cause of neurologic symptoms. MRI scanning, body scintigraphy and serum ALP levels enable the diagnostic of PDB. Therapeutic management of PDB with involvement of the nervous system should be adapted to the clinical presentation and based on bisphosphonates, decompressing of neural structures, and symptomatic treatment.

Supplementary materials

Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.radcr.2022.03.028.

References

[1] Alexandre C. Paget’s disease of bone [Article in French]. Encycl med-chir 2006;1(2):1–13. doi:10.1016/s0246-0521(06)41007-x.
[2] Feldman RG, Culebras A, Schmidek HH. Paget’s disease and the nervous system. J Am Geriatr Soc 1979;27(1):1–8. doi:10.1111/j.1532-5415.1979.tb01712.x.
[3] Singer FR, Bone HG 3rd, Hosking DJ, et al. Paget’s disease of bone: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2014;99(12):4408–22. doi:10.1210/jc.2014-2910.
[4] Direkze M, Fernando PS. Peripheral nerve entrapment in Paget’s disease. Acta Neuro Scand 1976;54(4):375–8. doi:10.1111/j.1600-0404.1976.tb04368.x.
[5] Ooi CG, Fraser WD. Paget’s disease of bone. Postgrad Med J 1997;73(856):69–74. doi:10.1136/pgmj.73.856.69.
[6] Clarke CR, Harrison MJ. Neurological manifestations of Paget’s disease. J Neurol Sci 1978;38(2):171–8. doi:10.1016/0022-510x(78)90063-1.
[7] Poncelet A. The neurologic complications of Paget’s disease. J Bone Miner Res 1999;14(Suppl 2):88–91.
[8] Sabur P, Poinsel E, Joubert C, Wybrecht D, Dagan A, Alla P, et al. Paget’s disease of bone, an unusual cause of trigeminal neuralgia [Article in French]. Prat neurol - FM C 2014;5(1):66–8. doi:10.1016/j.praneu.2014.01.001.
[9] Pane A. Paget disease manifesting with compressive sixth-nerve palsy that resolved with intravenous zolodronic acid therapy. Arch Ophthalmol 2007;125(10):1440–1. doi:10.1001/archoph.125.10.1440.
[10] Kristensen EB. Ocular manifestations in Paget’s disease (osteitis deformans). Report of a case with optic nerve involvement and ophthalmoplegia responding favourably to adrenocorticosteroid therapy. Acta Ophthalmol (Copenh). 1971;49(5):741–6. doi:10.1111/j.1755-3768.1971.tb08672.x.
[11] Delmas PD, Meunier PJ. The management of Paget’s disease of bone. N Engl J Med 1997;336(8):558–66. doi:10.1056/NEJM199702203360807.
[12] Wallace E, Wong J, Reid IR. Pamidronate treatment of the neurologic sequelae of pagetic spinal stenosis. Arch Intern Med 1995;155(16):1813–15. doi:10.1001/archinte.1995.00430160167017.